Brainomix and Boehringer Ingelheim have announced the expansion of their partnership to its next phase, a prospective multicenter study.
The study follows on from REVISE-PPF, a retrospective research study conducted with the University of Chicago, Weill Cornell Medical Center and the University of Alabama at Birmingham.
It evaluated Brainomix's e-Lung — an FDA-cleared, AI-driven imaging software platform that automatically detects and quantifies abnormalities on thoracic CT scans — in patients with progressive pulmonary fibrosis (PPF).
Built on proprietary technology, e-Lung has already been clinically validated to measure lung features associated with interstitial lung diseases (ILD).
The REVISE-PPF study demonstrated that e-Lung stratified patients at risk of PPF from baseline CTs and identified patients with radiologic evidence of PPF up to 28 months earlier than local clinical diagnoses.
The next phase of the partnership will centre on PROGRESS-PPF, a prospective multicentre study, to generate evidence of Branomix's e-Lung's clinical impact at scale, with deployments of e-Lung planned at numerous sites across the US.
Dr Michalis Papadakis, CEO and co-founder of Brainomix, said: "We are excited to expand our strategic partnership with Boehringer Ingelheim, a recognised leader and innovator in this field, with whom we share a firm commitment to improving outcomes for people living with pulmonary fibrosis."
The evidence generated to date for e-Lung is highly compelling, showing the technology has the potential to accelerate diagnosis by more than two years.
"This next phase will enable us to evaluate that potential at scale, providing robust real-world validation of what we expect could be a transformative advancement in the patient care pathway."
"Boehringer Ingelheim is proud to expand our partnership with Brainomix as part of our continued commitment to improving care for people living with pulmonary fibrosis," added Dr Emmanuelle Clerisme-Beaty, Senior Vice President, Medicine & Regulatory Affairs, Boehringer Ingelheim.
Progressive pulmonary fibrosis can be challenging to diagnose and innovations that enhance our ability to detect disease have the potential to improve patient outcomes.
An Innovation Hub session at ATS, entitled "Advancing ILD Care: Real-World Impact of Brainomix e-Lung," will take place on Tuesday, May 19th, during which Prof. Peter George (Consultant Pulmonologist at the Royal Brompton Hospital, UK and Brainomix Senior Medical Director) will speak with Dr Andy Limper (Mayo Clinic, Rochester) and Dr Tathagat Narula (Mayo Clinic, Jacksonville) about their institution's experience with Brainomix e-Lung, where it has been incorporated into routine clinical practice.
Brainomix will also be exhibiting the e-Lung technology at the ATS International Conference (booth #2250) from Sunday, May 17th, to Tuesday, May 19th.